Genmab A/S convened an Extraordinary General Meeting for October 7, 2026, to seek shareholder approval of Board remuneration for 2026 following the withdrawal of a similar proposal at its March Annual General Meeting. The Board recalibrated its peer group to an equal mix of U.S. and European companies but retained current remuneration levels and service-based RSU structures. Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.

Genmab A/S filed a 6-K report containing its updated Articles of Association. The company is a biotechnology firm focused on developing antibody therapeutics.